Fatemeh Sadat Hosseini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatemeh Sadat Hosseini has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Asghar Arshi
Young Researchers and Elite Club, Najafabad Branch, Islamic Azad University, Najafabad, Iran
1 shared publication - Fataneh Saleh Khaje Hosseini
PhD Student, Department of Counseling, Qom Branch, Islamic Azad University, Qom, Iran
1 shared publication Hossein Kerdarian
Students Research Committee, Babol University of Medical Science, Babol, Iran
1 shared publicationMahsa Sheikholia Lavasani
Human Genetic Research Center, Baqiyatallah University of Medical Science, Tehran, Iran
1 shared publication- Maryam Safarpour Dehkordi
Young Researchers and Elite club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
1 shared publication - Sayed Mostafa Hosseini
Chemical Injuries Research Center, Systems biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 5 February 2019
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (2) , 2059-2066
The anti-cancer effect of amygdalin on human cancer cell lines
Derived from rosaceous plant seed, amygdalin belongs to aromatic cyanogenic glycoside group, and its anticancer effects have been supported by mounting evidence. In this study, we objected to investigate amygdalin effect on two antiapoptotic genes (Survivin, XIAP) and two lncRNAs (GAS5, MALAT1) in human cancer cells (A549, MCF7, AGS). Employing RT-qPCR analysis, we compared the mRNA levels of the genes related to apoptosis in A549, MCF7, and AGS cancer cells between amygdalin-treated (24, 48 and 72 h) and un-treated groups. RNA was extracted from both cell groups and then cDNAs were synthesized. The changes in the gene expression levels were specified using ΔΔCt method. RT-qPCR analysis has revealed that the expression of Survivin, XIAP, GAS5 and MALAT1 in amygdala-treated cancer cells were significantly different, compared to the un-treated cells. However, these expressions were different depending on the treatment time. According to the results, amygdalin significantly inhibited the expression level of Survivin, and XIAP genes in treated via untreated group. Our findings suggest that amygdalin might have an anticancer effect due to the various gene expressions in A549, MCF7, and AGS human cancer cells, showing it’s potential as a natural therapeutic anticancer drug.
- 5 February 2019
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (2) , 2059-2066
The anti-cancer effect of amygdalin on human cancer cell lines
Derived from rosaceous plant seed, amygdalin belongs to aromatic cyanogenic glycoside group, and its anticancer effects have been supported by mounting evidence. In this study, we objected to investigate amygdalin effect on two antiapoptotic genes (Survivin, XIAP) and two lncRNAs (GAS5, MALAT1) in human cancer cells (A549, MCF7, AGS). Employing RT-qPCR analysis, we compared the mRNA levels of the genes related to apoptosis in A549, MCF7, and AGS cancer cells between amygdalin-treated (24, 48 and 72 h) and un-treated groups. RNA was extracted from both cell groups and then cDNAs were synthesized. The changes in the gene expression levels were specified using ΔΔCt method. RT-qPCR analysis has revealed that the expression of Survivin, XIAP, GAS5 and MALAT1 in amygdala-treated cancer cells were significantly different, compared to the un-treated cells. However, these expressions were different depending on the treatment time. According to the results, amygdalin significantly inhibited the expression level of Survivin, and XIAP genes in treated via untreated group. Our findings suggest that amygdalin might have an anticancer effect due to the various gene expressions in A549, MCF7, and AGS human cancer cells, showing it’s potential as a natural therapeutic anticancer drug.